WNK2 and Miyoshi myopathy: However, genome-wide next-generation sequencing (NGS) studies have provided a rationale for molecularly aimed treatment approaches by identifying specifically targetable mutations such as those in the mitogen-activated protein kinase (MAPK) pathway, which are the most prevalent mutations in MM [3-6].